Agenda:
Day One: 16 March 2005
08.00
Registration
09.00
BALLROOM: Chairman's Opening Welcome Address
Dr Kathleen Williams, Co-Chair of Life Sciences, Palmer & Dodge LLP
09.15
Keynote: Life Science Start-ups: Exploring the Adjacent Probable
Dr Noubar B. Afeyan, Senior Managing Director & CEO, Flagship Ventures
09.35
Keynote: Bio Defense - recognising the need for new therapeutics
Dr Ansbert Gadicke, Founding General Partner & Chairman, MPM Capital
09.55
Coffee Break
10.20
Small Cap Listed Company Presentations
Ballroom
Chair: Dr John Burt,
Thiakis		 Venetian Room
Chair: Richard Smith,
Palmer & Dodge		 Ballroom Foyer
Chair: Yvonne Wegmann, SWX Swiss Exchange
10.25
MethylGene, Inc.
Donald F. Corcoran,
President & CEO		 Avitar
Peter Phildius,
Chairman & CEO		 Emisphere Technologies, Inc.
Dr Michael M Goldberg,
Chairman & CEO
10.40
BioSante Phamaceuticals
Stephen Simes,
CEO		 Norwood Abbey
Bernie Romanin,
Senior Vice President Corporate Development		 Favrille
John Longenecker,
President & CEO
10.55
MacroChem
Robert DeLuccia,
President & CEO		 Biophan Technologies
Michael Weiner,
CEO		 Basilea Pharmaceutica
Dr Anthony Man,
CEO
11.10
Palatin Technologies
Dr Carl Spana,
President & CEO		 Life Medical Sciences
Robert P. Hickey,
President & CEO		 Diamyd Medical
Anders Essen-Moller,
CEO
11.25
Grant Life Sciences
Stan Yakatan,
CEO		 Viventia Biotech
Dr Nick Glover,
President & CEO		 VioQuest Pharmaceuticals
Daniel Greenleaf,
President & CEO
11.40
YM Biosciences
David Allan,
Chairman		 NovoDel Pharma
Dr Gary A. Shangold,
CEO		 Zeltia
Catherine Moukheibir, Director Capital Market Operations & Jose Jimeno,
VP Scientific Development, PharmaMar
11.55
Curis
Daniel Passeri,
President & CEO		 Adherex Technologies
Dr William Peters,
Chairman & CEO		  
12.10
Questions Questions Questions
12.15
Lunch
13.45 - 14.05
Keynote Address
Stelios Papadopoulos, Vice Chairman, SG Cowen Securities Corporation
14.05 - 14.20
Keynote: Overview of the European Capital Markets
Dr Heinrich Henkel, CEO, SWX Swiss Exchange
14.20 - 14.35
Keynote: Biotech Investing, now and then
Jean-François Formela, Senior Partner, Atlas Venture
14.35
Coffee Break
15.05
Venture Funded Early to Mid Stage Company Presentations
Ballroom
IMMUNOLOGY/ ONCOLOGY
Chair: Rhonda Chiger,
RX IR Communications		 Venetian Room
THERAPEUTICS
Chair: Donna LaVoie, LaVoie Strategic Communications Group		 Ballroom Foyer
THERAPEUTICS
Chair: Ira Leiderman,
The Trout Group
15.10
Avidex
James Noble,
CEO		 Aderis Pharmaceuticals
Kenneth L. Rice,
CFO & Chief Commercial Officer

atugen
Thomas Christély,
COO & CFO
15.25
ESBAtech
Dr Dominik Escher,
CEO		 Serenex
Dr Richard Kent,
CEO		 DeveloGen
Dr Guenther Karmann,
CEO
15.40
BioVex
Dr Tony Mills,
VP Business Development		 ACE Biosciences
Ingelise Saunders,
CEO 		EVOTEC Neurosciences
Dr John Kemp,
CEO
15.55
Bioxalis Medica
Vincent Lenaerts,
President & CEO		 Psychiatric Genomics
Dr Richard Chipkin, President & CEO		 Sirtris Pharmaceuticals
Dr Christoph Westphal,
CEO
16.10
Oncomethylome Sciences
Dr Herman Spolders,
CEO		 Ambit Biosciences
Scott Salka,
CEO		 PBL Therapeutics
Robert Pestka,
President & CEO
16.25
Intercell
Prof Alexander von Gabain,
CEO		 Lipocine
Jerry Simmons,
Corporate Business Development Officer		 MedExGen
Dr Yong-Hoon Chung,
President & CEO
16.40
Aegera Therapeutics Inc
Michael Atkin,
CEO		 NeuroMed Technologies
Dr Christopher C. Gallen, President & CEO		 Ablynx
Dr Mark Vaeck,
CEO
17.05
Cocktail Reception hosted by The American Stock Exchange
Day Two: 17 March 2005
08.00
Registration
08.45
BALLROOM: Chairman's Welcome Address
Mark R. Saunders, President, Global Markets Capital Group LLC
09.00
Panel Discusion: Venture Financing the way forward
Chair: Michael Lytton, General Partner, Oxford Bioscience Partners
Discussants: Jonathan Leff, Managing Director, Warburg Pincus
David Milne, General Partner, SV Life Sciences
09.45
Keynote Address
G. Steven Burrill, CEO, Burrill & Company
10.05
Venture Funded Early to Mid Stage Company Workshops
Ballroom:
IMMUNOLOGY/ONCOLOGY
Chair: Dr Anil Khurana,
Access International		 Venetian Room:
THERAPEUTICS
Chair: Christine Labaree,
The Trout Group
10.20
Aureon Biosciences Corporation
Vijay Aggarwal,
CEO & President		 Amphora Discovery Corporation
Peter G. Savas,
Chairman & Acting CEO
10.35
Librophyt
Alain Tissier,
CEO		 BioLine RX
Dr Morris Laster,
CEO
10.50
Pieris ProteoLab
Dr Martin Poelchen,
CEO		 Medicago
Andy Sheldon,
President & CEO
11.05
Topigen Pharmaceuticals
Dr Paul Wotton,
President & CEO		 TransPharma Medical
Dr Daphna Heffetz,
CEO
11.20
Xanthus Life Sciences
Robert Boisjoli, CA, CBV,
CFO		 Scil Technology
Dr Irina Staatz-Granzer,
Managing Director
11.35
POST GENOMICS
Iconix
Jim Neal,
CEO		 Arrow Therapeutics
Ian Garland,
CFO
11.50
Perlegen
Robert Middlebrook,
Chief Corporate Development Officer		 PolyMedix
Nick Landekic,
President & CEO
12.05
Questions Questions
12.15
Lunch
13.45
Panel Discussion: Why is Medtech Attracting New Investment?
Chair: William C Mills III, Managing Member, EGS Healthcare Capital Partners
Discussants:
Jan Wald, Analyst, AG Edwards & Sons
 Marc Goldberg, Managing Director, BioVentures Investors
Dr Lothar Krinke, Senior Director BioSciences Technology Development, Medtronic
Mark Chalek, Chief, Business Ventures, Beth Israel Deaconess Medical Centre
15.00
Panel Discussion: Bio Partnering and Collaborations between Pharmas and Biotechs
Chair: Dr Maggie Flanagan, Global Alliance Director, Enabling Science & Technology, AstraZeneca Pharmaceuticals
Discussants:
Dr Klaus Wilgenbus, Head of Corporate Division, Licensing, Boehringer Ingelheim
Steve Twait, Alliance Management, Eli Lilly & Co
Dr Robert Gould, Vice President, External Scientific Affairs Worldwide,
Merck & Co
16.00
Concluding Presentation: Global Themes: Looking ahead to 2006 and beyond
Stan Yakatan, Chairman, Katan Associates
16.20
Close of Conference
 

To download a pdf version of this agenda click here.

Back to top